TrialChest2026

Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS (Two Pivotal Studies to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-Severe COPD With Type 2 Inflammation).

Sanjay Ramakrishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.